— Positive review of all patient cohorts by Data Monitoring Committee —— ProSavin® provides long-term improvement of motor function — Oxford, UK – 15 December 2011: Oxford BioMedica plc (“Oxford BioMedica” or…
Oxford, UK – 16 November 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period…
— Research and development agreement signed with Mayo Clinic — Oxford, UK – 31 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the leading gene-based biopharmaceutical company,…
— Third ocular product partnered with Sanofi approved to enter clinical development — Oxford, UK – 18 October 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the…
Click here to download the full 2011 interim results statement.Click here to download the 2011 interim results slide deck. Oxford, UK – 31 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the…
— Positive interim review of fourth patient cohort by Data Monitoring Committee — Oxford, UK – 4 August 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), the…
— RetinoStat® Progress in Phase I Study in Wet Age-Related Macular Degeneration Oxford, UK – 22 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene…
— ‘In vivo’ diagnostic rights granted for cancer imaging — Oxford, UK – 7 June 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company,…
–Oxford BioMedica Appoints Alex Lewis as Director of Corporate Activities and Strategy– Oxford, UK – 24 May 2011: Oxford BioMedica (LSE: OXB), a leading gene therapy company, today announces that Dr…
— Six-month data from third cohort presented at ASGCT 14th Annual Meeting —— Highest efficacy results to date with 43% average motor function improvement — Oxford, UK – 23 May…
Oxford, UK – 18 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company, today publishes its interim management statement for the period from…
— Diagnostic rights secured for Investigational New Drug application — Oxford, UK – 4 May 2011: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE: OXB), a leading gene therapy company,…